Research Interest: Drug Discovery

PHD PROGRAM
Pharmaceutical Sciences

RESEARCH INTEREST
Chemical Biology, Drug Discovery, Translational Medicine

We are inspired by the diversity and complexity found in natural products and use their architecture as both a platform for developing chemical methods and as scaffolds for new molecular tools in chemical biology. We have employed our chemical synthesis skill set to solve emerging challenges facing modern medicine. This has led to ongoing collaborative projects in metastatic cancer, hepatitis C antivirals, dopamine signaling and sigma receptor ligands. Of particular interest is the development of next generation anti-metastasis agents to our recent phase I clinical candidate, metarrestin.

PHD PROGRAM

RESEARCH INTEREST
Cell Biology, Drug Discovery, Immunology

PHD PROGRAM

RESEARCH INTEREST
Drug Discovery, Pharmacology, Translational Medicine

PHD PROGRAM

RESEARCH INTEREST
Biochemistry, Drug Discovery, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Biophysics, Computational Biology, Drug Discovery

PHD PROGRAM

RESEARCH INTEREST
Chemical Biology, Drug Discovery, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Cancer Biology, Drug Discovery, Translational Medicine

PHD PROGRAM

RESEARCH INTEREST
Drug Discovery, Neurobiology, Pharmacology

PHD PROGRAM

RESEARCH INTEREST
Drug Discovery, Pharmacology

PHD PROGRAM
Microbiology & Immunology

RESEARCH INTEREST
Drug Discovery, Pathogenesis & Infection, Virology

Dr. Sheahan is an expert virologist with a primary appointment in the Department of Epidemiology in the Gillings School of Global Public Health and a secondary appointment in Microbiology and Immunology in the School of Medicine. His research is focused on understanding emerging viral diseases and developing new means to stop them with a current focus on coronavirus and hepacivirus.